ALX ONCOLOGY HOLDINGS INC

Listed Company

ALXOCIK 0001810182NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-101.69M

Total Assets

$59.05M

Equity

$25.98M

Shares Out

131.61M

Op. Cash Flow

$-84.14M

Business

ALX ONCOLOGY HOLDINGS INC is a clinical-stage immuno-oncology company developing therapies that block the CD47 immune checkpoint to engage macrophages and dendritic cells and bridge innate and adaptive anti-tumor immunity. Its main product candidate is evorpacept, a high-affinity SIRPα-based fusion protein with an inactivated Fc domain designed for combination use, alongside early programs including a TLR9-conjugate (ALTA-002) and an ADC program (ALX2004). The company operates through clinical development programs, strategic collaborations and investigator-sponsored trials and relies on contract manufacturers for supply. It conducts multinational clinical trials and intends to commercialize products in the United States and other regions, using partners and third-party distribution channels as needed.

Summary from filing dated 2025-03-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	77	116	142	98	60
General and administrative	24	26	28	29	23
Impairment charge	3	—	—	—	—
Total operating expenses	104	142	170	127	84
Loss from operations	−104	−142	−170	−127	−84
Interest income	4	9	11	4	91,000
Interest expense	−2	−2	−2	−238,000	−13,000
Other income (expense), net	−36,000	−20,000	389,000	−22,000	−7,000
Loss before income taxes	−102	−135	−161	−123	−83
Income tax provision	0	0	0	−64,000	21,000
Net loss	−102	−135	−161	−123	−83
Net loss per share, basic	−1.9	−2.58	−3.74	−3.03	−2.07
Net loss per share, diluted	−1.9	−2.58	−3.74	−3.03	−2.07
Weighted-average shares of common stock used to compute net loss per share, basic	54	52	43	41	40
Weighted-average shares of common stock used to compute net loss per share, diluted	54	52	43	41	40

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	16	18	22	49	364
Short-term investments	28	110	160	217	—
Prepaid expenses and other current assets	6	7	6	5	3
Total current assets	51	134	189	271	367
Property and equipment, net	1	3	4	4	897,000
Long-term investments	3	4	35	17	—
Other assets	4	7	15	15	12
Total assets	59	148	243	306	380
Accounts payable	5	4	9	8	4
Payable and accrued liabilities due to related party	0	149,000	543,000	2	—
Term loan, current	5	435,000	—	—	—
Accrued expenses and other current liabilities	14	13	27	19	10
Total current liabilities	25	19	36	28	15
Term loan, non-current, net	5	9	10	9	—
Other non-current liabilities	4	6	7	5	2
Total liabilities	33	34	53	43	17
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 54,388,022 and 53,052,912 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	54,000	53,000	50,000	41,000	41,000
Additional paid-in capital	749	734	676	590	565
Accumulated other comprehensive income	28,000	275,000	256,000	−845,000	—
Accumulated deficit	−723	−621	−486	−325	−202
Total stockholders equity	26	114	190	263	363
Total liabilities and stockholders equity	59	148	243	306	380

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−102	−135	−161	−123	−83
Stock-based compensation	13	27	26	24	14
Depreciation and amortization	706,000	872,000	836,000	342,000	51,000
Non-cash lease costs	2	2	1	1	685,000
Net accretion of discounts on investments	−1	−5	−6	−940,000	—
Accretion of term loan discount and issuance costs	280,000	265,000	250,000	44,000	—
Loss on disposal of fixed asset	—	10,000	—	—	—
Prepaid expenses and other current assets	658,000	−692,000	−1	−1	−2
Other assets	−686,000	7	1	750,000	−10
Accounts payable	421,000	−4	458,000	5	3
Payable and accrued liabilities due to related party	−149,000	−394,000	−1	20,000	1
Accrued expenses and other current liabilities	2	−13	11	7	3
Other non-current liabilities	−2	−2	−2	−977,000	−698,000
Net cash used in operating activities	−84	−122	−130	−89	−68
Purchase of investments	−52	−107	−247	−377	—
Maturities of investments	134	194	293	143	—
Purchase of property and equipment	−212,000	−447,000	−1	−1	−666,000
Net cash provided by investing activities	83	86	45	−235	−5
Proceeds from equity offerings, net of underwriter discounts ($3,795 thousand) and issuance costs ($567 thousand)	—	—	59	—	—
Proceeds from ATM offering, net of commissions	2	30	—	—	—
Proceeds from exercise of stock options under equity incentive plan	14,000	2	269,000	567,000	3
Proceeds from issuance of common stock under employee stock purchase plan	24,000	351,000	523,000	336,000	202,000
Principal payments on finance leases	−929,000	−827,000	−388,000	−388,000	−281,000
Principal payments on term loan	−435,000	—	—	—	—
Net cash provided by financing activities	362,000	31	59	10	2
Net (decrease) in cash, cash equivalents and restricted cash	−1	−5	−26	−315	−71
Cash paid for interest	1	1	1	103,000	11,000
Purchase of property and equipment in accounts payable and accrued expenses	962,000	1	1	2	237,000
Right-of-use asset (modified) acquired under finance leases	−182,000	1	3	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro